Compare BRX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRX | IMVT |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 8.0B |
| IPO Year | 2013 | 2019 |
| Metric | BRX | IMVT |
|---|---|---|
| Price | $31.01 | $38.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $31.58 | ★ $33.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.5M |
| Earning Date | 04-27-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,371,597,000.00 | N/A |
| Revenue This Year | $5.06 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | $76.10 | ★ N/A |
| Revenue Growth | ★ 6.73 | N/A |
| 52 Week Low | $24.66 | $14.32 |
| 52 Week High | $32.80 | $39.28 |
| Indicator | BRX | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 70.47 |
| Support Level | $30.79 | $25.13 |
| Resistance Level | $31.49 | N/A |
| Average True Range (ATR) | 0.54 | 1.33 |
| MACD | -0.13 | 0.12 |
| Stochastic Oscillator | 12.57 | 94.08 |
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.